One Year Results of Faricimab for Aflibercept-Resistant Diabetic Macular Edema

References

• Wells JA, Glassman AR, Ayala AR, et al.; Diabetic Retinopathy Clinical Research Network. Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372(13):1193–1203.
   PubMed Web of Science ®Google Scholar
• Elman MJ, Aiello LP, Beck RW, et al.; Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology. 2010;117(6):1064–1077 e35. doi:10.1016/j.ophtha.2010.02.031
   PubMed Web of Science ®Google Scholar
• Bressler SB, Ayala AR, Bressler NM, et al. Persistent macular thickening after ranibizumab treatment for diabetic macular edema with vision impairment. JAMA Ophthalmol. 2016;134(3):278–285. doi:10.1001/jamaophthalmol.2015.5346
   PubMed Web of Science ®Google Scholar
• Wykoff CC, Abreu F, Adamis AP, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, Phase 3 trials. Lancet. 2022;399(10326):741–755. doi:10.1016/S0140-6736(22)00018-6
   PubMed Web of Science ®Google Scholar
• Rush RB, Rush SW. Faricimab for treatment-resistant diabetic macular edema. Clin Ophthalmol. 2022;16:2797–2801. doi:10.2147/OPTH.S381503
   PubMed Web of Science ®Google Scholar
• Sarohia GS, Nanji K, Khan M, et al. Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: a systematic review and meta-analysis of 2346 eyes. Surv Ophthalmol. 2022;67(5):1346–1363. doi:10.1016/j.survophthal.2022.04.003
   PubMed Web of Science ®Google Scholar
• Chujo S, Sugimoto M, Sasaki T, et al. Comparison of 2-year outcomes between intravitreal ranibizumab and intravitreal aflibercept for diabetic macular edema with “Treat-and-Extend” regimen-its usefulness and problems. J Clin Med. 2020;9(9):2848. doi:10.3390/jcm9092848
   PubMed Web of Science ®Google Scholar
• Choi MY, Jee D, Kwon JW, Vavvas DG. Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS One. 2019;14(9):e0222364. doi:10.1371/journal.pone.0222364
   PubMed Web of Science ®Google Scholar
• Rahimy E, Shahlaee A, Khan MA, et al. Conversion to aflibercept after prior anti-VEGF therapy for persistent diabetic macular edema. Am J Ophthalmol. 2016;164:118–127.
   PubMed Web of Science ®Google Scholar
• Fechter C, Frazier H, Marcus WB, Farooq A, Singh H, Marcus DM. Ranibizumab 0.3 mg for persistent diabetic macular edema after recent, frequent, and chronic bevacizumab: the ROTATE trial. Ophthalmic Surg Lasers Imaging Retina. 2016;47(11):1–18. doi:10.3928/23258160-20161031-07
   PubMed Web of Science ®Google Scholar
• Huang WH, Lai CC, Chuang LH, et al. Foveal microvascular integrity association with anti-VEGF treatment response for diabetic macular edema. Invest Ophthalmol Vis Sci. 2021;62(9):41. doi:10.1167/iovs.62.9.41
   PubMed Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Maguire MG, et al.;Diabetic Retinopathy Clinical Research Network. Early response to anti-vascular endothelial growth factor and two-year outcomes among eyes with diabetic macular edema in protocol T. Am J Ophthalmol. 195;2018:93–100. doi:10.1016/j.ajo.2018.07.030
   PubMed Web of Science ®Google Scholar
• Ashraf M, Souka AA, ElKayal H. Short-term effects of early switching to ranibizumab or aflibercept in diabetic macular edema cases with non-response to bevacizumab. Ophthalmic Surg Lasers Imaging Retina. 2017;48(3):230–236. doi:10.3928/23258160-20170301-06
   PubMed Web of Science ®Google Scholar
• Laiginhas R, Silva MI, Rosas V, et al. Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Graefes Arch Clin Exp Ophthalmol. 2018;256(1):83–89. doi:10.1007/s00417-017-3836-1
   PubMed Web of Science ®Google Scholar
• Bahrami B, Hong T, Schlub TE, Chang AA. Aflibercept for persistent diabetic macular edema: forty-eight-week outcomes. Retina. 2019;39(1):61–68. doi:10.1097/IAE.0000000000002253
   PubMed Web of Science ®Google Scholar
• Bressler NM, Beaulieu WT, Glassman AR, et al. Persistent macular thickening following intravitreous aflibercept, bevacizumab, or ranibizumab for central-involved diabetic macular edema with vision impairment: a secondary analysis of a randomized clinical trial. JAMA Ophthalmol. 2018;136(3):257–269. doi:10.1001/jamaophthalmol.2017.6565
   PubMed Web of Science ®Google Scholar
• Liberski S, Wichrowska M, Kociecki J. Aflibercept versus faricimab in the treatment of neovascular age-related macular degeneration and diabetic macular edema: a review. Int J Mol Sci. 2022;23(16):9424. doi:10.3390/ijms23169424
   PubMed Web of Science ®Google Scholar
• Hussain RM, Neiweem AE, Kansara V, et al. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019;28(10):861–869. doi:10.1080/13543784.2019.1667333
   PubMed Web of Science ®Google Scholar
• Ferro Desideri L, Traverso CE, Nicolò M. The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases. Expert Opin Ther Targets. 2022;26(2):145–154. doi:10.1080/14728222.2022.2036121
   PubMed Web of Science ®Google Scholar
• Sadda SR, Campbell J, Dugel PU, et al. Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: a post hoc analysis of Protocol I data. Eye. 2020;34(3):480–490. doi:10.1038/s41433-019-0522-z
   PubMed Web of Science ®Google Scholar